Regulation - GlaxoSmithKline, Pricing

Filter

Current filters:

GlaxoSmithKlinePricing

Popular Filters

IQWiG sees benefits for Triumeq and Eperzan

05-02-2015

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) has announced its latest findings…

Anti-viralsDiabetesEperzanGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTriumeqViiV Healthcare

ViiV’s Triumeq offers added benefit for treatment-naive adults with HIV, says IQWiG

ViiV’s Triumeq offers added benefit for treatment-naive adults with HIV, says IQWiG

08-01-2015

Germany’s Institute for Quality and Efficiency in Health Care (IQWiG), which had already assessed a…

Anti-viralsGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTriumeqViiV Healthcare

India’s National Pharmaceutical Pricing Authority caps price of 52 more drugs

India’s National Pharmaceutical Pricing Authority caps price of 52 more drugs

15-12-2014

The National Pharmaceutical Pricing Authority (NPPA) of India has issued a notice capping prices of 52…

BaxterGlaxoSmithKlineIndiaPharmaceuticalPricingRegulationWockhardt

NICE recommends another new skin cancer drug, GSK’s Tafinlar

22-10-2014

The UK National Institute for Health and Care Excellence (NICE) has issued final guidance recommending…

GlaxoSmithKlineOncologyPharmaceuticalPricingRegulationTafinlarUK

IQWiG finds no added benefit for GSK’s Anoro Ellipta in COPD

21-10-2014

According to the findings of an early benefit assessment under the German Act on the Reform of the Market…

Anoro ElliptaGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationRespiratory and Pulmonary

UK’s NICE proposes to recommend GSK’s Tafinlar for melanoma

UK’s NICE proposes to recommend GSK’s Tafinlar for melanoma

18-09-2014

UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has issued final draft…

GlaxoSmithKlineOncologyPharmaceuticalPricingRegulationRocheTafinlarUKZelboraf

IQWIG finds added benefit in adult patients for VIIV Healthcare’s Tivicay

27-05-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Anti-viralsGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationTivicayViiV Healthcare

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

GSK’s Tafinlar also no added benefit over vemurafenib, says IQWiG

09-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlarvemurafenib

IQWiG says added benefit of GSK’s Tafinlar not proven

IQWiG says added benefit of GSK’s Tafinlar not proven

07-01-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyGlaxoSmithKlineNorthern EuropeOncologyPharmaceuticalPricingRegulationTafinlar

New Zealand funding plans for Tarceva and Revolade

New Zealand funding plans for Tarceva and Revolade

09-12-2013

Following a consultation, New Zealand’s Pharmaceutical Management Agency PHARMAC said this morning…

Asia-PacificGlaxoSmithKlineHematologyNew ZealandOncologyPharmaceuticalPricingRegulationRevoladeRocheTarceva

UK’s NICE issues draft guidance on suite of ovarian cancer drugs

27-09-2013

Drugs watchdog the National Institute for Health and Care Excellence (NICE) is currently considering…

Europegemcitabine HclGlaxoSmithKlineJohnson & JohnsonLillyOncologyPharmaceuticalPricingRegulationtrabectedin

New Zealand proposals for influenza vaccines

21-08-2013

New Zealand's Pharmaceutical Management Agency PHARMAC is seeking feedback on a proposal to list two…

Abbott LaboratoriesAsia-PacificFluarixGlaxoSmithKlineInfluvacPharmaceuticalPricingRegulationVaccines

Pharma giants included in China's investigation into pricing of foreign imports

05-07-2013

China's National Development and Reform Commission (NDRC) has launched an investigation into UK pharma…

Astellas PharmaBaxterBoehringer IngelheimGlaxoSmithKlineJiangsu Hengrui MedicinePharmaceuticalPricingRegulationSandozSinopharm Group

Positive NICE news for GSK's Revolade and InterMune's Esbriet

21-03-2013

UK drugs watchdog the National Institute for Health and Clinical Excellence today (March 21) issued two…

BiotechnologyEsbrietEuropeGlaxoSmithKlineImmunologicalsInterMunePharmaceuticalPricingRegulationRespiratory and PulmonaryRevolade

UK NICE agrees to reconsider decision to deny NHS access to GSK's Benlysta

07-09-2012

The UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) confirmed this…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlinePharmaceuticalPricingRare diseasesRegulation

Final guidance from UK NICE on Tarceva, Tyverb, Herceptin, Zytiga and Botox

26-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has today published…

AllerganBotoxEuropeGlaxoSmithKlineHerceptinJanssenJohnson & JohnsonNeurologicalOncologyPharmaceuticalPricingRegulationRocheTarcevaTyverbZytiga

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra

09-05-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

UK NICE gives draft "No" to Benlysta, and negative final guidance for Tyverb and Herceptin

27-04-2012

There was a batch of bad news emanating from the US drugs watchdog the National Institute for Health…

Anti-Arthritics/RheumaticsBenlystaEuropeGlaxoSmithKlineHerceptinOncologyPharmaceuticalPricingRare diseasesRegulationRocheTyverb

Back to top